CeriBell, Inc. (CBLL)
| Market Cap | 929.13M +105.9% |
| Revenue (ttm) | 101.96M +31.7% |
| Net Income | -66.00M |
| EPS | -1.76 |
| Shares Out | 38.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 450,191 |
| Open | 24.50 |
| Previous Close | 24.40 |
| Day's Range | 24.16 - 25.00 |
| 52-Week Range | 10.85 - 25.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.00 (+11.52%) |
| Earnings Date | Aug 10, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $27.0, which is an increase of 11.52% from the latest price.
News
Ceribell price target raised to $30 from $28 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Ceribell (CBLL) to $30 from $28 and keeps a Buy rating on the shares. The company has established itself as…
CeriBell Transcript: Canaccord Genuity's 46th Annual Growth Conference
Rapid EEG technology with AI is driving improved outcomes and expanding into new indications, supported by strong clinical data and favorable reimbursement. Sales force productivity and strategic account management are expected to boost growth, with new products and market segments launching over the next two years.
Ceribell price target raised to $26 from $25 at Canaccord
Canaccord raised the firm’s price target on Ceribell (CBLL) to $26 from $25 and keeps a Buy rating on the shares. The firm said Ceribell delivered another small beat &…
Ceribell reports Q2 EPS (51c), consensus (46c)
Reports Q2 revenue $28.1M, consensus $27.28M. Total revenue increased 33% year-over-year, driven primarily by continued growth in new account additions and increased utilization within existing accoun...
Ceribell raises FY26 revenue view to $114M-$117M from $112M-$116M
Consensus $114M. The updated outlook represents growth of approximately 28% to 31% over the company’s prior year revenue. This reflects continued momentum in its core business, driven by both new…
CeriBell Earnings Call Transcript: Q2 2026
Q2 2026 saw 33% revenue growth to $28.1M, record gross margins, and strong account expansion. FDA clearances, new product launches, and CMS reimbursement for Delirium monitoring set the stage for continued growth, with 2026 guidance raised and significant contributions from new products expected in 2027.
CeriBell Earnings release: Q2 2026
CeriBell released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
CeriBell Quarterly report: Q2 2026
CeriBell has published its Q2 2026 quarterly earnings report on August 10, 2026.
Ceribell announces FDA clearance for two new AI algorithm enhancements
CeriBell (CBLL) announced FDA 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact...
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of p...
CeriBell Slides: Corporate presentation
CeriBell has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Ceribell secures CMS NTAP for Delirium Monitor System
CeriBell (CBLL) announced that the U.S. Centers for Medicare & Medicaid Services, or CMS, has granted a new technology add-on payment, or NTAP, for up to $2,171 per eligible Medicare…
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind ...
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe
SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell Slides: Corporate presentation
CeriBell has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System ...
CeriBell Transcript: 46th Annual William Blair Growth Stock Conference
A novel rapid EEG platform with AI-driven seizure detection is expanding into pediatrics, neonates, and delirium, nearly doubling its addressable market. Strong revenue growth, high margins, and a scalable business model support continued expansion, with new clinical pilots and regulatory milestones ahead.
CeriBell Transcript: AGM 2026
The meeting confirmed quorum, elected two directors, and ratified the independent auditor for 2026. Voting followed company bylaws, and an informal Q&A was held after official business.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serio...
CeriBell Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 revenue and account growth were driven by sales force maturation, new strategies targeting regional hospital systems, and strong product adoption. New indications in neonate and delirium are progressing well, with positive early feedback and ongoing clinical research. Gross margin improved to 87% due to cost management and supply chain diversification.
Ceribell price target lowered to $25 from $28 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Ceribell (CBLL) to $25 from $28 and keeps a Buy rating on the shares. The firm said Ceribell posted another…
Ceribell reports Q1 EPS (52c), consensus (39c)
Reports Q1 revenue $26.5M, consensus $26.09M. “Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring pla...
Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M
16:09 EDT Ceribell (CBLL) sees FY26 revenue $112M-$116M, consensus $113.18M